Table 2.
Schizophrenia Subjects Demographics
| Medicated (n=18) | Unmedicated (n=7) | Statistics | |||
|---|---|---|---|---|---|
| Variable | Mean or n | SD or % | Mean or n | SD or % | p-value |
| Age (years) | 35.7 | 10.9 | 32.3 | 12.9 | 0.515 |
| Education (years) | 13.1 | 1.5 | 13.3 | 1.5 | 0.805 |
| BMI | 30.7 | 4.1 | 30.7 | 7.6 | 0.994 |
| NART | 108.4 | 8.1 | 111.9 | 9.6 | 0.377 |
| FTND | 2.2 | 2.7 | 1.4 | 2.4 | 0.527 |
| Injected Activity [mCi] | 13.64 | 3.96 | 15.18 | 2.71 | 0.36 |
| Injected Mass [μg] | 3.84 | 3.29 | 3.25 | 3.23 | 0.69 |
| Specific Activity [mCi/nmol] | 3.40 | 2.78 | 5.01 | 5.17 | 0.32 |
| Free Fraction (fp) | 0.001 | 0.0004 | 0.001 | 0.004 | 0.26 |
| Duration since antipsychotic exposure (months) | N.A | - | 27* | 24 | |
| Tobacco Smoker (No/Yes) | 9/9 | 50/50 | 5/2 | 71/29 | 0.4 |
| Race (White/AA/Other) | 11/6/1 | 61/33/6 | 4/3/0 | 57/43/0 | |
| Ethnicity (Non-Hispanic/Hispanic) | 16/2 | 89/11 | 5/2 | 71/29 | |
| Lifetime Cannabis Exposure** (No/Yes) | 5/12 | 29/71 | 2/4 | 33/66 | 1 |
| Recent Cannabis exposure (No/Yes) | 17/1 | 94.5/0.05 | 7/0 | 100/0 | 0.5 |
Medicated = receiving antipsychotic treatment; Unmedicated = not receiving antipsychotic treatment;
NART = National Adult Reading Test; BMI = Body Mass Index; FTND = Fagerstrom Tobacco Test for Nicotine Dependence; AA = African American
*
Range (2 months – 60 months); One patient was antipsychotic naïve.
**
Lifetime cannabis use data are missing in 2 SCZs (neither subject met criteria for any lifetime cannabis use disorder).